Neurocritical Care News

The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive dyskinesia, according to a press release from the manufacturer.

DENVER — Daily treatment with a suspension of gold crystals was linked to improved outcomes at 96 weeks for those with stable relapsing multiple sclerosis, according to a speaker at the American Academy of Neurology annual meeting.

Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for Alzheimer’s disease, one which detects glial fibrillary acidic protein and another for phosphorylated tau.

The FDA has approved an abbreviated new drug application for naloxone hydrochloride nasal spray, paving the way for the opioid overdose treatment to be available without a prescription.

DENVER — A combination therapeutic for amyotrophic lateral sclerosis was nonsuperior to placebo over 48 weeks in a phase 3 clinical trial, according to a presenter at the American Academy of Neurology annual meeting.

DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole.

Therapist burnout was associated with lower odds of clinically meaningful improvement among patients being treated for PTSD, according to a study published in JAMA Network Open.

DENVER — Deterioration of memory and executive functions were associated with worsening quality of life for those with Parkinson’s disease over a 3-year period, according to a poster at the American Academy of Neurology annual meeting.

DENVER — Exposure to airborne manganese may be a significant contributing factor to risk of Parkinson’s disease, according to a poster from the American Academy of Neurology annual meeting.

Nearly all study participants believed to have a synucleinopathy had the presence of alpha-synuclein in their skin samples, according to a study presented at the American Academy of Neurology annual meeting.